Cargando…

The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use

PURPOSE: To evaluate the potential of Danish prescription registries to capture aspirin and non-aspirin non-steroidal anti-inflammatory drug (NSAID) use and to quantitatively evaluate the magnitude of bias from misclassification of true NSAID and aspirin use as apparent non-use in drug outcome studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaster, Natascha, Hallas, Jesper, Pottegård, Anton, Friis, Søren, Schmidt, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286082/
https://www.ncbi.nlm.nih.gov/pubmed/34285591
http://dx.doi.org/10.2147/CLEP.S311450
_version_ 1783723671603380224
author Gaster, Natascha
Hallas, Jesper
Pottegård, Anton
Friis, Søren
Schmidt, Morten
author_facet Gaster, Natascha
Hallas, Jesper
Pottegård, Anton
Friis, Søren
Schmidt, Morten
author_sort Gaster, Natascha
collection PubMed
description PURPOSE: To evaluate the potential of Danish prescription registries to capture aspirin and non-aspirin non-steroidal anti-inflammatory drug (NSAID) use and to quantitatively evaluate the magnitude of bias from misclassification of true NSAID and aspirin use as apparent non-use in drug outcome studies. PATIENTS AND METHODS: In a population-based cohort study, we retrieved sales statistics for NSAIDs and aspirins based on nationwide data from the Danish Health Data Authority and the Danish National Prescription Registry. We estimated prevalence of recorded and non-recorded NSAID use in the prescription registry and resulting proportions of true NSAID and aspirin use misclassified as apparent non-use from 1999 to 2019 at population and patient levels. RESULTS: The prevalence of true use misclassified as non-use (mainly due to over-the-counter use) peaked at 4.7% in 2012 for NSAIDs overall, 5.5% in 2012 for ibuprofen, and at 5.9% in 2002 for high-dose aspirin. Misclassification of other individual NSAIDs was near null. Misclassification of true low-dose aspirin use as non-use declined during the study period but remained around 1% since 2005. In subgroups of cardiac patients, the highest prevalence of true NSAID use misclassified as non-use was 5.0% in 2002 and 4.3% in 2017. Quantitative bias analyses showed how such misclassification of true NSAID and aspirin use as non-use remained minimal both at population and patient levels. In hypothetical examples simulating real study populations with differing exposure prevalence and prevalence of true NSAID and aspirin use misclassified as apparent non-use, the approximate percentage change due to misclassification of use as non-use did not exceed 5% and in most scenarios stayed around 1%. CONCLUSION: The Danish prescription registries are valid data sources for assessing the effects of aspirin and NSAID use. The influence of non-recorded NSAID and aspirin use on estimates of association is virtually negligible.
format Online
Article
Text
id pubmed-8286082
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82860822021-07-19 The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use Gaster, Natascha Hallas, Jesper Pottegård, Anton Friis, Søren Schmidt, Morten Clin Epidemiol Original Research PURPOSE: To evaluate the potential of Danish prescription registries to capture aspirin and non-aspirin non-steroidal anti-inflammatory drug (NSAID) use and to quantitatively evaluate the magnitude of bias from misclassification of true NSAID and aspirin use as apparent non-use in drug outcome studies. PATIENTS AND METHODS: In a population-based cohort study, we retrieved sales statistics for NSAIDs and aspirins based on nationwide data from the Danish Health Data Authority and the Danish National Prescription Registry. We estimated prevalence of recorded and non-recorded NSAID use in the prescription registry and resulting proportions of true NSAID and aspirin use misclassified as apparent non-use from 1999 to 2019 at population and patient levels. RESULTS: The prevalence of true use misclassified as non-use (mainly due to over-the-counter use) peaked at 4.7% in 2012 for NSAIDs overall, 5.5% in 2012 for ibuprofen, and at 5.9% in 2002 for high-dose aspirin. Misclassification of other individual NSAIDs was near null. Misclassification of true low-dose aspirin use as non-use declined during the study period but remained around 1% since 2005. In subgroups of cardiac patients, the highest prevalence of true NSAID use misclassified as non-use was 5.0% in 2002 and 4.3% in 2017. Quantitative bias analyses showed how such misclassification of true NSAID and aspirin use as non-use remained minimal both at population and patient levels. In hypothetical examples simulating real study populations with differing exposure prevalence and prevalence of true NSAID and aspirin use misclassified as apparent non-use, the approximate percentage change due to misclassification of use as non-use did not exceed 5% and in most scenarios stayed around 1%. CONCLUSION: The Danish prescription registries are valid data sources for assessing the effects of aspirin and NSAID use. The influence of non-recorded NSAID and aspirin use on estimates of association is virtually negligible. Dove 2021-07-13 /pmc/articles/PMC8286082/ /pubmed/34285591 http://dx.doi.org/10.2147/CLEP.S311450 Text en © 2021 Gaster et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gaster, Natascha
Hallas, Jesper
Pottegård, Anton
Friis, Søren
Schmidt, Morten
The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use
title The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use
title_full The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use
title_fullStr The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use
title_full_unstemmed The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use
title_short The Validity of Danish Prescription Data to Measure Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Quantification of Bias Due to Non-Prescription Drug Use
title_sort validity of danish prescription data to measure use of aspirin and other non-steroidal anti-inflammatory drugs and quantification of bias due to non-prescription drug use
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286082/
https://www.ncbi.nlm.nih.gov/pubmed/34285591
http://dx.doi.org/10.2147/CLEP.S311450
work_keys_str_mv AT gasternatascha thevalidityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT hallasjesper thevalidityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT pottegardanton thevalidityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT friissøren thevalidityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT schmidtmorten thevalidityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT gasternatascha validityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT hallasjesper validityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT pottegardanton validityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT friissøren validityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse
AT schmidtmorten validityofdanishprescriptiondatatomeasureuseofaspirinandothernonsteroidalantiinflammatorydrugsandquantificationofbiasduetononprescriptiondruguse